DE602005020326D1 - Diagnose und therapie von zellproliferationkrankheiten die durch trail resistenz apoptose gekennzeichnet sind - Google Patents

Diagnose und therapie von zellproliferationkrankheiten die durch trail resistenz apoptose gekennzeichnet sind

Info

Publication number
DE602005020326D1
DE602005020326D1 DE602005020326T DE602005020326T DE602005020326D1 DE 602005020326 D1 DE602005020326 D1 DE 602005020326D1 DE 602005020326 T DE602005020326 T DE 602005020326T DE 602005020326 T DE602005020326 T DE 602005020326T DE 602005020326 D1 DE602005020326 D1 DE 602005020326D1
Authority
DE
Germany
Prior art keywords
diagnosis
therapy
cell proliferation
proliferation diseases
diseases indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005020326T
Other languages
English (en)
Inventor
Stephan Wolf
Stefan Joss
Daniel Mertens
Armin Pscherer
Peter Lichter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of DE602005020326D1 publication Critical patent/DE602005020326D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005020326T 2004-10-08 2005-10-10 Diagnose und therapie von zellproliferationkrankheiten die durch trail resistenz apoptose gekennzeichnet sind Active DE602005020326D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04024054A EP1645875A1 (de) 2004-10-08 2004-10-08 Diagnose und Therapie von Zellproliferationskrankheiten die durch TRAIL Resistenz Apoptose gekennzeichnet sind
PCT/EP2005/010885 WO2006037660A2 (en) 2004-10-08 2005-10-10 Diagnosis and therapy of cell proliferative disorders characterized by resistance to trail induced apoptosis

Publications (1)

Publication Number Publication Date
DE602005020326D1 true DE602005020326D1 (de) 2010-05-12

Family

ID=34926920

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005020326T Active DE602005020326D1 (de) 2004-10-08 2005-10-10 Diagnose und therapie von zellproliferationkrankheiten die durch trail resistenz apoptose gekennzeichnet sind

Country Status (5)

Country Link
US (1) US20090203587A1 (de)
EP (2) EP1645875A1 (de)
AT (1) ATE462974T1 (de)
DE (1) DE602005020326D1 (de)
WO (1) WO2006037660A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011080314A2 (en) * 2009-12-31 2011-07-07 Deutsches Krebsforschungszentrum Novel modulators of trail signalling
JP5918143B2 (ja) * 2010-10-29 2016-05-18 第一三共株式会社 新規抗ｄｒ５抗体
RU2620165C2 (ru) * 2015-08-31 2017-05-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ индукции гибели опухолевых клеток

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
IL136156A0 (en) * 2000-05-16 2001-05-20 Compugen Ltd Sequences of trail variants
AU2002258399A1 (en) * 2001-02-16 2002-09-19 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer

Also Published As

Publication number Publication date
EP1797424B1 (de) 2010-03-31
EP1645875A1 (de) 2006-04-12
EP1797424A2 (de) 2007-06-20
ATE462974T1 (de) 2010-04-15
WO2006037660A2 (en) 2006-04-13
US20090203587A1 (en) 2009-08-13
WO2006037660A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
Borgi et al. Stress and coping in women with breast cancer: unravelling the mechanisms to improve resilience
TW200531682A (en) Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
JP2009514881A5 (de)
MX2009004786A (es) Derivados de anilinopiperazina y sus metodos de uso.
Blumberger et al. Repetitive transcranial magnetic stimulation for refractory symptoms in schizophrenia
EP3050566A3 (de) Neue gruppe von stat3-pfad-hemmern und krebs-stammzell-pfad-hemmer
MX2007000606A (es) Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
DE60329756D1 (de) Mitotische kinesin-hemmer
JP2009514880A5 (de)
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
MX2010008021A (es) Nuevos derivados de n-(2-amino-fenil)-amida.
EA201170831A1 (ru) Аминопиразольное соединение
DE602005020326D1 (de) Diagnose und therapie von zellproliferationkrankheiten die durch trail resistenz apoptose gekennzeichnet sind
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
NO20054631D0 (no) Antistoff mot tumorspesifikt antigen som mal
Ma et al. AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
GB2462715A (en) Imidazole derivatives that induce apoptosis and their therapeutic uses
WO2013001369A3 (en) Therapeutic and diagnostic target
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
ATE435224T1 (de) Neue piperidinsubstituierte diaminothiazole
NO20092496L (no) Ny terapeutisk anvendelse for behandling av leukemi

Legal Events

Date Code Title Description
8364 No opposition during term of opposition